Latest news with #vMap
Yahoo
3 days ago
- Health
- Yahoo
First Patients Enrolled in IMPRoVED-AF Study Using vMap, a Non-Invasive ECG-Based Tool Designed to Guide More Effective AF Ablation
Prospective, Multi-Center Study Aims to Build Evidence Demonstrating How Arrhythmia Analysis Tool Enhances Treatment for Persistent and Recurrent AF SAN DIEGO, July 09, 2025--(BUSINESS WIRE)--Vektor Medical, a medical technology company transforming standard ECG data into actionable insights that guide arrhythmia care, today announced that Baptist Health Lexington has enrolled the first patients in the IMPRoVED-AF clinical study. Baptist Health Lexington, a 434-bed acute care hospital, is a long-time leader in innovative approaches to treat heart disease and related conditions. IMPRoVED-AF is a prospective, randomized, controlled, international, multi-center study designed to rigorously compare clinical outcomes in patients undergoing pulmonary vein isolation (PVI) alone versus PVI and additional driver ablation guided by vMap®, the only FDA-cleared non-invasive arrhythmia analysis technology designed to improve, enhance, and accelerate ablation procedures, utilizing data from a standard 12-lead ECG. The study aims to demonstrate the comparative clinical benefit of using vMap to identify and ablate non-pulmonary vein electrical drivers, when used alongside standard-of-care ablation techniques, including advanced technologies such as pulsed field ablation (PFA), in patients with persistent and recurrent atrial fibrillation (AF). "Enrolling the first patient in the IMPRoVED-AF study marks an important milestone in our ongoing efforts at Baptist Health to further advance care for our patients suffering from cardiac arrhythmias," said Dr. Gery Tomassoni, Principal Investigator and cardiac electrophysiologist at Baptist Health Lexington. "For patients with persistent and recurrent AF, treatment has often been ineffective due to the inability to identify the source of the arrhythmia. Using vMap to determine a targeted ablation strategy beyond the pulmonary veins provides an opportunity to target drivers that were previously undetectable. That means better care and more effective, lasting results for patients." With growing pressure to improve outcomes and reduce re-do procedures, physicians and hospitals are seeking non-invasive tools that can improve targeting while maintaining necessary workflow efficiencies. vMap is designed to address this need by delivering rapid analysis and insights from a standard 12-lead ECG. "The IMPRoVED-AF study is an important validation of the meaningful impact vMap is already delivering in the EP lab," said Rob Krummen, CEO of Vektor Medical. "This isn't about incremental improvement; it's a leap forward in how we identify and treat complex arrhythmias. vMap is uncovering drivers that often go undetected, helping physicians deliver more effective and durable outcomes. This study is a critical part of our strategy to build the clinical evidence that drives confident adoption, supports value in health systems, and positions vMap as the new standard in arrhythmia care." The IMPRoVED-AF study, managed by Veranex, a global leader in clinical research, will enroll up to 384 patients with persistent and recurrent AF at approximately 20 electrophysiology centers across the United States and Europe. The primary endpoint of the study is freedom from AF at 12 months. To learn more about the IMPRoVED-AF study, explore vMap technology, or request a clinical or strategic briefing, visit and connect with us on LinkedIn and X. About vMap® vMap is the only FDA-cleared, non-invasive solution that transforms data from a standard 12-lead ECG into actionable insights to guide arrhythmia care. The technology, developed with AI, localizes arrhythmia source locations across all four chambers of the heart — including both focal and fibrillation-type arrhythmias. vMap is used by electrophysiologists during triage, procedural planning, and ablation to help identify and target arrhythmia drivers more quickly and with greater confidence. Backed by growing clinical evidence, use of vMap has been associated with improved outcomes, reduced procedure time, and streamlined workflow across the arrhythmia care continuum. About Vektor Medical Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is working to improve outcomes, enhance efficiencies, and accelerate access to effective treatment strategies. To learn more, visit View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@
Business Wire
3 days ago
- Health
- Business Wire
First Patients Enrolled in IMPRoVED-AF Study Using vMap, a Non-Invasive ECG-Based Tool Designed to Guide More Effective AF Ablation
SAN DIEGO--(BUSINESS WIRE)-- Vektor Medical, a medical technology company transforming standard ECG data into actionable insights that guide arrhythmia care, today announced that Baptist Health Lexington has enrolled the first patients in the IMPRoVED-AF clinical study. Baptist Health Lexington, a 434-bed acute care hospital, is a long-time leader in innovative approaches to treat heart disease and related conditions. With growing pressure to improve outcomes and reduce re-do procedures, physicians and hospitals are seeking non-invasive tools that can improve targeting while maintaining necessary workflow efficiencies. vMap is designed to address this need... Share IMPRoVED-AF is a prospective, randomized, controlled, international, multi-center study designed to rigorously compare clinical outcomes in patients undergoing pulmonary vein isolation (PVI) alone versus PVI and additional driver ablation guided by vMap®, the only FDA-cleared non-invasive arrhythmia analysis technology designed to improve, enhance, and accelerate ablation procedures, utilizing data from a standard 12-lead ECG. The study aims to demonstrate the comparative clinical benefit of using vMap to identify and ablate non-pulmonary vein electrical drivers, when used alongside standard-of-care ablation techniques, including advanced technologies such as pulsed field ablation (PFA), in patients with persistent and recurrent atrial fibrillation (AF). 'Enrolling the first patient in the IMPRoVED-AF study marks an important milestone in our ongoing efforts at Baptist Health to further advance care for our patients suffering from cardiac arrhythmias,' said Dr. Gery Tomassoni, Principal Investigator and cardiac electrophysiologist at Baptist Health Lexington. 'For patients with persistent and recurrent AF, treatment has often been ineffective due to the inability to identify the source of the arrhythmia. Using vMap to determine a targeted ablation strategy beyond the pulmonary veins provides an opportunity to target drivers that were previously undetectable. That means better care and more effective, lasting results for patients.' With growing pressure to improve outcomes and reduce re-do procedures, physicians and hospitals are seeking non-invasive tools that can improve targeting while maintaining necessary workflow efficiencies. vMap is designed to address this need by delivering rapid analysis and insights from a standard 12-lead ECG. 'The IMPRoVED-AF study is an important validation of the meaningful impact vMap is already delivering in the EP lab,' said Rob Krummen, CEO of Vektor Medical. 'This isn't about incremental improvement; it's a leap forward in how we identify and treat complex arrhythmias. vMap is uncovering drivers that often go undetected, helping physicians deliver more effective and durable outcomes. This study is a critical part of our strategy to build the clinical evidence that drives confident adoption, supports value in health systems, and positions vMap as the new standard in arrhythmia care.' The IMPRoVED-AF study, managed by Veranex, a global leader in clinical research, will enroll up to 384 patients with persistent and recurrent AF at approximately 20 electrophysiology centers across the United States and Europe. The primary endpoint of the study is freedom from AF at 12 months. To learn more about the IMPRoVED-AF study, explore vMap technology, or request a clinical or strategic briefing, visit and connect with us on LinkedIn and X. About vMap® vMap is the only FDA-cleared, non-invasive solution that transforms data from a standard 12-lead ECG into actionable insights to guide arrhythmia care. The technology, developed with AI, localizes arrhythmia source locations across all four chambers of the heart — including both focal and fibrillation-type arrhythmias. vMap is used by electrophysiologists during triage, procedural planning, and ablation to help identify and target arrhythmia drivers more quickly and with greater confidence. Backed by growing clinical evidence, use of vMap has been associated with improved outcomes, reduced procedure time, and streamlined workflow across the arrhythmia care continuum. About Vektor Medical Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is working to improve outcomes, enhance efficiencies, and accelerate access to effective treatment strategies. To learn more, visit
Business Wire
23-04-2025
- Health
- Business Wire
Vektor Medical Announces Post-Market Study Evaluating Benefit of AI-Powered Analysis to Identify and Ablate Non-Pulmonary Vein AF Targets
SAN DIEGO--(BUSINESS WIRE)-- Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the IMPRoVED AF clinical study designed to evaluate the benefit of utilizing AI-driven mapping to identify and ablate non-pulmonary vein electrical drivers implicated in persistent and recurrent atrial fibrillation (AF). "The IMPRoVED-AF trial represents a landmark moment for Vektor, validating vMap's clinical efficacy and demonstrating our ability to dramatically improve outcomes and redefine arrhythmia care." Rob Krummen, CEO, Vektor Medical IMPRoVED AF (artificial Intelligence Mapping and ablation of non-PulmonaRy Vein Electrical Drivers of AF) is a prospective, randomized, controlled, multi-center study clinical trial that will rigorously compare clinical outcomes in patients undergoing pulmonary vein isolation (PVI) alone versus PVI and additional driver ablation guided by Vektor's proprietary vMap technology. vMap is the only FDA-cleared non-invasive AI-powered arrhythmia analysis technology designed to improve, enhance, and accelerate ablation procedures, utilizing data from a standard 12-lead ECG. 'Persistent and recurrent AF remains incredibly challenging, profoundly affecting patient quality of life and burdening our healthcare systems,' said Dr. Gery Tomassoni, Principal Investigator and cardiac electrophysiologist at Baptist Health Lexington. 'The IMPRoVED AF study is positioned to address this challenge. By leveraging AI-driven technology, we aim to significantly enhance ablation accuracy and effectiveness, potentially redefining the standard for managing persistent AF.' The study, managed by clinical research organization Veranex, will enroll up to 384 patients with persistent (not longstanding) and recurrent AF at 15 electrophysiology centers across the United States and Europe. The study's design specifically aims to demonstrate the comparative clinical benefit of utilizing AI-driven mapping to identify and ablate non-pulmonary vein electrical hotspots in accordance with standard-of-care ablation practices. The primary endpoint of the study is freedom from AF on or off antiarrhythmic drugs at 12 months. Additional secondary endpoints include: freedom from AF and atrial tachycardia on and off antiarrhythmic drugs at 12 months total procedure time total vMap mapping time AF burden as a proportion of time before versus after ablation proportion of subjects with AF terminated spontaneously upon and after the first ablation, and total fluoroscopy dose. Interim results are anticipated by HRS 2026; comprehensive results are expected at HRS 2027. 'EPs can't ablate what they can't identify. That's exactly why vMap was created - to empower EPs with actionable insights previously inaccessible from a standard ECG,' said Rob Krummen, CEO of Vektor Medical. 'The IMPRoVED AF trial represents a landmark moment for Vektor, validating vMap's clinical efficacy and demonstrating our ability to dramatically improve outcomes and redefine arrhythmia care. Re-do procedures have unfortunately become the norm, underscoring the critical need for technologies that provide additional insight on arrhythmia sources.' In parallel with the IMPRoVED AF study, Vektor has also initiated the VITAL-EP registry to collect real-world data on the clinical utility, safety, and procedural efficiency of vMap-guided ablation procedures. The registry, managed by clinical research organization Heart Rhythm Clinical and Research Solutions, aims to enroll at least 110 patients across four sites. The registry will evaluate multiple procedural-related endpoints, including AF termination or AF non-inducibility in AF ablation cases and procedure efficiency, including procedure duration and fluoroscopy use. About vMap ® vMap is the only FDA-cleared, non-invasive AI-based solution for mapping arrhythmias, utilizing just a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillation-type arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway. About Vektor Medical Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit Connect with Vektor Medical on LinkedIn and X.
Yahoo
23-04-2025
- Health
- Yahoo
Vektor Medical Announces Post-Market Study Evaluating Benefit of AI-Powered Analysis to Identify and Ablate Non-Pulmonary Vein AF Targets
IMPRoVED AF RCT and VITAL-EP Registry Reinforce Vektor's Focus on Data That Drives EP Adoption and Ablation Outcomes SAN DIEGO, April 23, 2025--(BUSINESS WIRE)--Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the IMPRoVED AF clinical study designed to evaluate the benefit of utilizing AI-driven mapping to identify and ablate non-pulmonary vein electrical drivers implicated in persistent and recurrent atrial fibrillation (AF). IMPRoVED AF (artificial Intelligence Mapping and ablation of non-PulmonaRy Vein Electrical Drivers of AF) is a prospective, randomized, controlled, multi-center study clinical trial that will rigorously compare clinical outcomes in patients undergoing pulmonary vein isolation (PVI) alone versus PVI and additional driver ablation guided by Vektor's proprietary vMap technology. vMap is the only FDA-cleared non-invasive AI-powered arrhythmia analysis technology designed to improve, enhance, and accelerate ablation procedures, utilizing data from a standard 12-lead ECG. "Persistent and recurrent AF remains incredibly challenging, profoundly affecting patient quality of life and burdening our healthcare systems," said Dr. Gery Tomassoni, Principal Investigator and cardiac electrophysiologist at Baptist Health Lexington. "The IMPRoVED AF study is positioned to address this challenge. By leveraging AI-driven technology, we aim to significantly enhance ablation accuracy and effectiveness, potentially redefining the standard for managing persistent AF." The study, managed by clinical research organization Veranex, will enroll up to 384 patients with persistent (not longstanding) and recurrent AF at 15 electrophysiology centers across the United States and Europe. The study's design specifically aims to demonstrate the comparative clinical benefit of utilizing AI-driven mapping to identify and ablate non-pulmonary vein electrical hotspots in accordance with standard-of-care ablation practices. The primary endpoint of the study is freedom from AF on or off antiarrhythmic drugs at 12 months. Additional secondary endpoints include: freedom from AF and atrial tachycardia on and off antiarrhythmic drugs at 12 months total procedure time total vMap mapping time AF burden as a proportion of time before versus after ablation proportion of subjects with AF terminated spontaneously upon and after the first ablation, and total fluoroscopy dose. Interim results are anticipated by HRS 2026; comprehensive results are expected at HRS 2027. "EPs can't ablate what they can't identify. That's exactly why vMap was created - to empower EPs with actionable insights previously inaccessible from a standard ECG," said Rob Krummen, CEO of Vektor Medical. "The IMPRoVED AF trial represents a landmark moment for Vektor, validating vMap's clinical efficacy and demonstrating our ability to dramatically improve outcomes and redefine arrhythmia care. Re-do procedures have unfortunately become the norm, underscoring the critical need for technologies that provide additional insight on arrhythmia sources." In parallel with the IMPRoVED AF study, Vektor has also initiated the VITAL-EP registry to collect real-world data on the clinical utility, safety, and procedural efficiency of vMap-guided ablation procedures. The registry, managed by clinical research organization Heart Rhythm Clinical and Research Solutions, aims to enroll at least 110 patients across four sites. The registry will evaluate multiple procedural-related endpoints, including AF termination or AF non-inducibility in AF ablation cases and procedure efficiency, including procedure duration and fluoroscopy use. About vMap® vMap is the only FDA-cleared, non-invasive AI-based solution for mapping arrhythmias, utilizing just a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillation-type arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway. About Vektor Medical Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit Connect with Vektor Medical on LinkedIn and X. View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@
Business Wire
21-04-2025
- Health
- Business Wire
The Future of AI & Electrophysiology Takes Center Stage at Heart Rhythm 2025 with Vektor Medical
SAN DIEGO--(BUSINESS WIRE)-- Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, will showcase its transformative vMap technology at Heart Rhythm 2025, taking place April 25–27 in San Diego. Through live demonstrations at adjacent booths (#1523 and #1622), scientific abstract presentations, and a highly anticipated Rhythm Theater session featuring leading electrophysiologists, Vektor will offer attendees a firsthand look at how vMap is being integrated into clinical workflows to support more informed, efficient, and effective ablation strategies. This unique, data-driven approach is helping EPs accelerate diagnosis, enhance procedural accuracy, and improve outcomes across the arrhythmia care spectrum. Share vMap is the only FDA-cleared, AI-based arrhythmia analysis solution that uses a standard 12-lead ECG to non-invasively localize arrhythmia sources, including both focal and fibrillation-type rhythms. This unique, data-driven approach is helping EPs accelerate diagnosis, enhance procedural accuracy, and improve outcomes across the arrhythmia care spectrum. Experience vMap in Action Visit Booths #1523 and #1622 (side-by-side) to explore how vMap is redefining arrhythmia source localization. See firsthand how physicians use the technology to improve outcomes, streamline workflows, and expand access to effective treatment. Schedule a one-on-one demo with the Vektor team here. Rhythm Theater Session 'AI and PFA: A Complementary Approach to Arrhythmia Treatment' Saturday, April 26 | 9:15 – 10:00 a.m. | Rhythm Theater 2 Moderated by Dr. Devi Nair, Director of Cardiac Electrophysiology at St. Bernards Heart & Vascular, this session will spotlight how AI-powered ECG analysis elevates the standard of care in EP labs. The panel will also explore how vMap integrates with pulsed field ablation (PFA) and other advanced treatment strategies. Panelists and discussion topics include: Dr. Gery Tomassoni, Baptist Health Lexington: Non-PV Driver Ablation with vMap and Upcoming Clinical Studies Dr. Benjamin D'Souza, Penn Medicine: vMap's Role in VT Ablation and Procedural Outcomes Dr. Anish Amin, OhioHealth: Integrating vMap into AF Ablation Procedures with PFA Scientific Abstract Presentations Mapping of Unstable Scar Mediated Ventricular Tachycardias: A Novel Technique Saturday, April 26 | 9:30 – 11:30 a.m. Dr. Faris Haddadin Abstract Pavilion Optimizing Procedural Techniques for Improved Ablation Outcomes Sunday, April 27 | 8:00 – 9:00 a.m. 'Prospective Non-Invasive Artificial Intelligence-Based CT and ECG Localization of Scar-Based Ventricular Arrhythmias' - Dr. Gordon Ho Oral Abstract Hub 1 – Sails Pavilion 'vMap addresses a critical gap in arrhythmia care,' said Rob Krummen, CEO of Vektor Medical. 'Electrophysiologists across the U.S. are using vMap to guide ablation strategies with greater confidence, and the results are gaining attention. At HRS, we are proud to showcase that impact through live demos and by amplifying the voices of the physicians using this technology every day. As we prepare to launch multiple key clinical studies, including our pivotal randomized trial, we are deepening the clinical foundation for broader adoption. This is a pivotal moment—for Vektor and the future of electrophysiology.' About vMap® vMap is the only FDA-cleared, non-invasive AI-powered solution for mapping arrhythmias, utilizing just a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillatory arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway. About Vektor Medical Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit Connect with Vektor Medical on LinkedIn and X.
